EPCORE FL-1 Results Show Significance of Epcoritamab Combo in Follicular Lymphoma

News
Video

The primary end points of the EPCORE FL-1 trial were met while assessing an epcoritamab-based combination for patients with R/R follicular lymphoma.

Updated results from the phase 3 EPCORE FL-1 trial (NCT05409066) assessing epcoritamab-bysp (Epkinly) plus rituximab (Rituxan) and lenalidomide (Revlimid) for patients with relapsed/refractory follicular lymphoma were recently announced.

The results showed the trial met the primary end point of overall response rate (P <.0001) and progression-free survival (HR, 0.21; P <.0001). The risk of disease progression or death was reduced by 79%. Additional presentation of these results is expected to be submitted to the American Society of Hematology for the 2025 Annual Meeting and Exposition.

The FDA has set a Prescription Drug User Fee Act Date of November 30, 2025. If this regimen is approved, it will become the first bispecific antibody combination available in the US as second-line therapy for this disease state.

Because of these new data, CancerNetwork® spoke with Julie M. Vose, MD, MBA, George and Peggy Payne Distinguished Chair of Oncology, chief of Oncology & Hematology, professor of Oncology & Hematology at the University of Nebraska Medical Center, and co-editor-in-chief of ONCOLOGY®. She highlighted why these results were so significant and how these data can be used long-term.

Transcript:

EPCORE FL-1 is a clinical trial using a bispecific antibody, [epcoritamab], and now has some long-term data. This information is shown in several different types of lymphoma; diffuse large B-cell, follicular lymphoma, and there is a bit of data in other types of B-cell lymphomas, but those are the 2 most common. What is important from this long-term data is that there are [many] patients who are staying on the treatment long-term and are able to tolerate it well. There are [numerous] patients who have this long-term data that are staying in remission off therapy, even though it has been stopped; it appears that the remissions are durable in a percentage of patients. This is important. It is a whole new class of drugs that have only been available for a short period of time, but these long-term data from the original clinical trials are showing us that it may have long-term benefits, even though the treatment has been stopped.

Reference

Genmab announces phase 3 EPCORE® FL-1 clinical trial met dual primary endpoints in patients with relapsed/refractory (R/R) follicular lymphoma (FL). News release. Genmab. August 7, 2025. Accessed August 12, 2025. https://tinyurl.com/4nhj3566

Recent Videos
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
CAR T-cell therapies or other agents that impact the immune system in the long term may be important to keep in mind for the management of SCLC.
Marc S. Raab, MD, PhD, details how agents like carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Patients with mantle cell lymphoma who are older and have less fitness may be eligible for regimens that include bendamustine/rituximab.
Employing patient-reported outcomes may help include those with small cell lung cancer in the shared decision-making process.
Related Content